ENROLL FOR CLINIC SERVICE
ENROLL OR ASK FOR PRICE
Innovative and Effective Treatment
for Metastatic Prostate Cancer
FREQUENTLY OBSERVED ADVERSE REACTIONS:
The majority of patients treated with 177Lu-PSMA do not experience serious adverse reactions. The most frequent are:
- Dry mouth and/or eyes (up to 30% of patients).
- Nausea and vomiting (up to 10% of patients).
- Haematopoietic suppression in patients with metastatic bone lesions.
PATIENT SELECTION CRITERIA:
INCLUSION CRITERIA:
- Patients with metastatic castration-resistant prostate cancer (mCRPC) for whom the available approved (alternative) treatment methods have been exhausted or are not suitable.
- Patients who have previously undergone the following examinations:
- PET/CT with PSMA, not earlier than 2 months before the 177Lu-PSMA therapy, which confirms the increased PSMA expression.
- A complete blood count with serum biochemistry, including ASAT, ALT, creatinine, PSA level in the serum, not earlier than 10 days prior to 177Lu-PSMA therapy.
- Information about the stage of the disease before the treatment, information about the treatments applied, previous examinations, histological results.
- The patient agrees to the use of anonymized data for research purposes.
- The decision on the appropriateness of 177Lu-PSMA therapy for each specific patient is made by the consortium of specialist doctors.
EXCLUSION CRITERIA:
- General health status according to the Karnofsky > 70 points, unless the aim of the therapy is to reduce symptoms of the disease.
- Severe dysfunction of the urinary system (obstruction, hydronephrosis).
- Advancing and uncontrolled illnesses, including liver and kidney diseases, and infections.
- Suppression of the bone marrow function:
- leukocyte count < 2.5 x 109/L
- thrombocyte count < 75 x 109/L
